论文部分内容阅读
目的：总结青年人肺癌的治疗结果，探讨其临床特点及影响预后的因素。方法：采用ＳＴＡＴＡ５０统计软件，建立１１１例≤４０岁手术切除的青年人肺癌的病例资料数据库并进行统计分析。生存率用寿命表法计算，生存率差异的显著性检验用Ｌｏｇｒａｎｋ检验。结果：本组并发症发生率为１０８１％，无术后３０天死亡。根治术５年生存率４６８６％，高于姑息术３３３３％（Ｐ＞００５）。不同ＴＮＭ分期的５年生存率分别为：Ⅰ期６１５６％，Ⅱ期２６７４％，Ⅲａ期３０４６％及Ⅳ期３３３３％。Ⅰ期与Ⅱ期比较Ｐ＜００１。在综合治疗组中，小细胞肺癌及Ｎ２患者５年生存率分别为５５５６％及４５４５％，而单一手术组均无１年生存者（Ｐ＜０００１）。在姑息性手术病例中，综合治疗组的５年生存率为４４４４％，而单一手术组无３年生存者（Ｐ＞００５）。结论：ＴＮＭ分期、综合治疗是影响预后的主要因素。综合治疗是提高姑息手术、小细胞肺癌和Ｎ２患者生存的关键。
OBJECTIVE: To summarize the treatment outcomes of young people with lung cancer, to explore their clinical features and factors that influence their prognosis. Methods:Statistical software STATA50 was used to establish a database of 111 cases of young patients with lung cancer who were ≤40 years old and analyzed statistically. The survival rate was calculated using the life table method, and the significance test of the difference in survival rate was examined using Logrank. Results: The complication rate in this group was 10.81%, and no death occurred 30 days after operation. The 5-year survival rate of radical mastectomy was 46.6%, which was 33.33% higher than that of palliative surgery (P>0. 05). The 5-year survival rates for different TNM staging were: 61.6% for phase I, 26.4% for phase II, 30.6% for phase IIIa, and 33.33% for phase IV. Phase I vs Phase II P<001. In the comprehensive treatment group, the 5-year survival rates of small cell lung cancer and N2 patients were 55.6% and 45.5%, respectively, while none of the single-operation groups had 1-year survival (P<0.001). In palliative surgery cases, the 5-year survival rate of the combined treatment group was 44. 44%, while the single-operation group had no 3-year survival (P > 0. 05). Conclusion: TNM staging and comprehensive treatment are the main factors affecting the prognosis. Comprehensive treatment is the key to improving the survival of palliative surgery, small cell lung cancer, and N2 patients.